On the stock market since 2007, it operates in the world of health and science. It has 257 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 26% a year on average.
Sales run at $41.0M a year. A small number, but proof the product has real buyers.
There is $39.7M in the vault; even if every debt were paid off, $33.7M would remain.
A loss of $10.9M against $41.0M in annual sales.
The price action doesn’t yet back an upward turn.
On our five-subject report card, ITMR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ITMR is a high-risk stock — not yet profitable, and its future rides on its product catching on.